We evaluated the effect of rapid ART (RA) compared to delayed ART (DA) on viral load suppression (viral load <50 cp/mL) and loss to follow-up (LTFU) in a cohort of migrants living with HIV (MLWHs) in Italy.
Methods
Data were retrospectively gathered from MLWHs who began care at the Infectious and Tropical Diseases Unit of the Careggi University Hospital from January 2014 to December 2022. RA was defined as antiretrovirals prescribed within 7 days of HIV diagnosis. The study ended on April 30, 2023, or upon patient LTFU. Chi-square and non-parametric tests assessed differences in categorical and continuous variables, respectively. Kaplan-Meyer survival analysis was performed to estimate the probability of loss to follow-up. Cox regression analysis was performed to evaluate factors associated with a loss to follow-up.
Results
87 MLWHs were enrolled: 20 (23%) on RA and 67 (77%) on DA. In the RA group there were more PLWH with a previous AIDS event (p < .001) however, there was no significant difference in the LTFU rates between the groups (aHR 0.6, 95%CI 0.1-3.1; p = .560; Logrank = 0.2823). Being an out-of-status MLWH was the only predictor of LTFU. By 6 months, virological suppression was achieved in 61.2% (n = 41) in DA and 70.0% in the RA group (n = 14) (Logrank p = .6747).
Conclusions
RA did not significantly affect LTFU rates or the achievement of viral load suppression. The study suggests that further research is needed to assess the impact of RA in high income settings.
Reyes-UrueñaJMarroneGNooriT, et al.HIV diagnoses among people born in Ukraine reported by EU/EEA countries in 2022: impact on regional HIV trends and implications for healthcare planning. Euro Surveill2023; 28(48): 2300642.
YinZBrownAERiceBD, et al.Post-migration acquisition of hiv: Estimates from four european countries, 2007 to 2016. Euro Surveill2021; 26: 2000161. European Centre for Disease Prevention and Control (ECDC).
FakoyaIÁlvarez-Del ArcoDWoode-OwusuM, et al.A systematic review of post-migration acquisition of HIV among migrants from countries with generalised HIV epidemics living in Europe: mplications for effectively managing HIV prevention programmes and policy. BMC Publ Health2015; 15: 561.
7.
RossJCunninghamCOHannaDB. HIV outcomes among migrants from low-income and middle-income countries living in high-income countries: a review of recent evidence. Curr Opin Infect Dis2018; 31: 25–32.
8.
BilJPZuureFRAlvarez-Del ArcoD, et al.Disparities in access to and use of HIV-related health services in The Netherlands by migrant status and sexual orientation: a cross-sectional study among people recently diagnosed with HIV infection. BMC Infect Dis2019; 19(1): 906.
9.
World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring : recommendations for a public health approach, p. 548.
10.
MoranLKoesterKALe TourneauN, et al.The Rapid interaction: a qualitative study of provider approaches to implementing Rapid ART. Implement Sci Commun2023; 4(1): 78.
11.
MgbakoOLoughranCMathuR, et al.Rapid or immediate ART, HIV stigma, medical Mistrust, and retention in care: an exploratory mixed methods pilot study. AIDS Behav2023; 27: 3430–3446.
12.
BoydMABoffitoMCastagnaA, et al.Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps. HIV Med2019; 20: 3–11.
13.
Mateo-UrdialesAJohnsonSSmithR, et al.Rapid initiation of antiretroviral therapy for people living with HIV. Cochrane Database Syst Rev2019; 17: CD012962.
14.
WoldesenbetSAKufaTBarronP, et al.Viral suppression and factors associated with failure to achieve viral suppression among pregnant women in South Africa. AIDS2020; 34(4): 589–597.
15.
DahTTEYayaIMensahE, et al.Rapid antiretroviral therapy initiation and its effect on treatment response in MSM in West Africa. AIDS2021; 35(13): 2201–2210.
16.
MichienziSMBarriosMBadowskiME. Evidence regarding rapid initiation of antiretroviral therapy in patients living with HIV. Curr Infect Dis Rep2021; 23: 7. DOI: 10.1007/s11908-021-00750-5.
17.
RosenSMaskewMFoxMP, et al.Initiating antiretroviral therapy for HIV at a patient's first clinic visit: the RapIT randomized controlled trial. PLoS Med2016; 13(5): e1002015.
18.
HoeniglMChaillonAMooreDJ, et al.Rapid HIV viral load suppression in those initiating antiretroviral therapy at first visit after HIV diagnosis. Sci Rep2016; 6: 32947.
19.
KoenigSPDorvilNDévieuxJG, et al.Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: a randomized unblinded trial. PLoS Med2017; 14(7): e1002357.
20.
CoffeySBacchettiPSachdevD, et al.RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population. AIDS2019; 33(5): 825–832.
21.
HuhnGDCrofootGRamgopalM, et al.Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in a rapid-initiation model of care for human immunodeficiency virus type 1 infection: primary analysis of the DIAMOND study. Clin Infect Dis2020; 71(12): 3110–3117.
22.
HalperinJConnerKButlerI, et al.A care continuum of immediate ART for newly diagnosed patients and patients presenting later to care at a federally qualified health center in new orleans. Open Forum Infect Dis2019; 6(4): ofz161.
23.
LabhardtNDRingeraILejoneTI, et al.Effect of offering same-day ART vs usual health facility referral during home-based HIV testing on linkage to care and viral suppression among adults with HIV in Lesotho. JAMA2018; 319: 1103–1112.
24.
ZolopaARAndersenJPowderlyL, et al.Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One2009; 4(5): e5575.
25.
MurenziGKimHYShiQ, et al.Association between time to antiretroviral therapy and loss to care among newly diagnosed Rwandan people living with human immunodeficiency virus. AIDS Res Hum Retrovir2023; 39(5): 253–261.
26.
TaylorBSReyesELevineEA, et al.Patterns of geographic mobility predict barriers to engagement in HIV care and antiretroviral treatment adherence. AIDS Patient Care STDS2014; 28(6): 284–295.
27.
GregoriNRenzettiSIzzoI, et al.Does the rapid initiation of antiretroviral therapy at HIV diagnosis impact virological response in a real-life setting? A single-centre experience in Northern Italy. AIDS Care2023; 35(12): 1938–1947.
28.
AntinoriA. Therapy initiation and rapid start with Bictegravir/Emtricitabine/Tenofovir Alafenamide in PLWH. Infez Med2023; 31: 277–282.
29.
GianottiNGalliLSampaoloM, et al.No need to modify treatment within the first month after rapid start of a tailored antiretroviral therapy: the TWODAY Study. New Microbiol2023; 46: 154–160.
30.
BavaroDFDe VitoAPasculliG, et al.Early versus delayed antiretroviral therapy based on genotypic resistance test: results from a large retrospective cohort study. J Med Virol2022; 94(8): 3890–3899.
